{"id":"niperotidine","rwe":[{"pmid":"15073985","year":"1998","title":"Ocular disorders in users of H2 antagonists and of omeprazole.","finding":"","journal":"Pharmacoepidemiology and drug safety","studyType":"Clinical Study"},{"pmid":"9314138","year":"1997","title":"Acute liver injury related to the use of niperotidine.","finding":"","journal":"Journal of hepatology","studyType":"Clinical Study"},{"pmid":"1983712","year":"1990","title":"The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring.","finding":"","journal":"The Italian journal of gastroenterology","studyType":"Clinical Study"}],"tags":[{"label":"niperotidine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H2 receptor","category":"target"},{"label":"HRH2","category":"gene"},{"label":"A02BA05","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"perultid","offLabel":[],"synonyms":["piperonyl ranitidine hydrochloride","niperotidine hydrochloride","niperotidine","piperonyl ranitidine HCl","niperotidine HCl","perultid"],"timeline":[],"approvals":[],"brandName":"Perultid","ecosystem":[],"mechanism":{"target":"Histamine H2 receptor","targets":[{"gene":"HRH2","source":"DrugCentral","target":"Histamine H2 receptor","protein":"Histamine H2 receptor"}],"modality":"Small Molecule","drugClass":"niperotidine","explanation":"Imagine your stomach lining has special receptors that respond to histamine, a chemical that tells your stomach to produce more acid. Perultid blocks these receptors, so your stomach doesn't get the signal to produce as much acid. This can help with conditions like ulcers or acid reflux.","oneSentence":"Perultid works by blocking histamine receptors in the stomach to reduce acid production.","technicalDetail":"Perultid acts as a competitive antagonist at the histamine H2 receptor, inhibiting the binding of histamine and subsequent activation of the receptor, which leads to a decrease in gastric acid secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4002","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NIPEROTIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIPEROTIDINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:58:32.542248","biosimilars":[],"competitors":[{"drugName":"cimetidine","drugSlug":"cimetidine","fdaApproval":"1977-08-16","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ranitidine","drugSlug":"ranitidine","fdaApproval":"1977-08-29","genericCount":44,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"famotidine","drugSlug":"famotidine","fdaApproval":"1986-10-15","genericCount":54,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nizatidine","drugSlug":"nizatidine","fdaApproval":"1988-04-12","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"niperotidine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cimetidine","brandName":"cimetidine","genericName":"cimetidine","approvalYear":"1977","relationship":"same-class"},{"drugId":"ranitidine","brandName":"ranitidine","genericName":"ranitidine","approvalYear":"1977","relationship":"same-class"},{"drugId":"famotidine","brandName":"famotidine","genericName":"famotidine","approvalYear":"1986","relationship":"same-class"},{"drugId":"nizatidine","brandName":"nizatidine","genericName":"nizatidine","approvalYear":"1988","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02555852","phase":"","title":"Proton Pump Inhibitors and Risk of Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-09","conditions":["Gastroesophageal Reflux Disease (GERD)","Community-acquired Pneumonia"],"enrollment":4238504,"completionDate":"2012-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"12JBD7U72K","CHEBI":"CHEBI:135706","INN_ID":"5857","UMLSCUI":"C0650638","ChEMBL_ID":"CHEMBL4297186","KEGG_DRUG":"D07072","DRUGBANK_ID":"DB13760","PUBCHEM_CID":"3033952","MESH_SUPPLEMENTAL_RECORD_UI":"C073716"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A02BA05","allCodes":["A02BA05"]},"biosimilarFilings":[],"recentPublications":[{"date":"1998 Jul","pmid":"15073985","title":"Ocular disorders in users of H2 antagonists and of omeprazole.","journal":"Pharmacoepidemiology and drug safety"},{"date":"1997 Sep","pmid":"9314138","title":"Acute liver injury related to the use of niperotidine.","journal":"Journal of hepatology"},{"date":"1990 Oct","pmid":"1983712","title":"The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring.","journal":"The Italian journal of gastroenterology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perultid (Niperotidine) is a small molecule drug that targets the histamine H2 receptor. It is a member of the niperotidine class and works by blocking the action of histamine at the H2 receptor, which is involved in stomach acid production. Perultid is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unknown. As a result, its safety profile and key considerations are also not well established. Further research is needed to determine the potential benefits and risks of this drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}